comparemela.com

Therapy Summit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023

ROCKVILLE, Md., May 22, 2023 /PRNewswire/ REGENXBIO Inc. today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene. | May 22, 2023

Chris brinzeyDana cormackTechnology platformCorporate communicationsTechnology platform licenseesBarclays gene editingTherapy summitGene editingGenomic medicinesAre we readyPlatform licenseesRegenxbio inc stock exchangePress releaseArclays rgnx us75901b1070

Beam Therapeutics to Participate in Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 17, 2023 Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate. | May 17, 2023

United kingdomDan budwickChelcie listerStrategic communicationsBeam therapeutics incVirtual gene editingTherapy summitVirtual genetic medicinesBeam therapeutics inc stock exchangePress releaseO beam us07373v1052

Intellia Therapeutics, Inc : Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND

New yorkUnited statesUnited kingdomIan karpRebecca spaldingJohn leonardAlina liBill chaseLas vegasExchange commissionCompany environmentalVivo program updatesRegeneron pharmaceuticals incIntellia therapeutics incTherapeutics incHealth care conference

Muscular Dystrophy Association Announces Nearly $400K in

New York, NY, March 13, 2023 (GLOBE NEWSWIRE) Today, Muscular Dystrophy Association (MDA) announced two research grants designed to address potential.

United statesNew yorkSan antonioDriscoll children hospitalBaylor college of medicineUniversity of texasCarrie miceliJeffrey chamberlainSharon hesterleeUniversity of california los angelesSchool of medicineInstitute for stem cell regenerative medicineChildren medical centerCare center networkUniversity of washingtonCook children medical center

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomLoma linda universityUnited statesSan franciscoNiva russekJeremy shefnerJeffrey rosenfeldCharles duncanFerenc tracikShiran zimriNedira salzman frenkelAmyotrophic lateral sclerosis consortiumNeurosense head of the scientific programCompany investigational new drugPrnewswire neurosense therapeutics ltdDrug administration

vimarsana © 2020. All Rights Reserved.